Free Trial

Diaceutics (LON:DXRX) Sets New 1-Year High - Here's Why

Diaceutics logo with Medical background

Diaceutics PLC (LON:DXRX - Get Free Report)'s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as GBX 151 ($1.87) and last traded at GBX 145.50 ($1.80), with a volume of 416157 shares. The stock had previously closed at GBX 137.50 ($1.70).

Wall Street Analysts Forecast Growth

DXRX has been the subject of a number of recent research reports. Canaccord Genuity Group reissued a "buy" rating and set a GBX 160 ($1.98) price target on shares of Diaceutics in a research note on Tuesday, December 17th. Canaccord Genuity Group reiterated a "buy" rating and set a GBX 160 ($1.98) target price on shares of Diaceutics in a research report on Tuesday, December 17th.

Read Our Latest Report on DXRX

Diaceutics Trading Up 5.8 %

The company has a market capitalization of £122.90 million, a P/E ratio of -4,850.00 and a beta of 0.58. The business has a 50 day moving average price of GBX 121.93 and a 200 day moving average price of GBX 126.46. The company has a current ratio of 4.85, a quick ratio of 9.92 and a debt-to-equity ratio of 2.93.

About Diaceutics

(Get Free Report)

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Further Reading

Should You Invest $1,000 in Diaceutics Right Now?

Before you consider Diaceutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diaceutics wasn't on the list.

While Diaceutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines